LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended September 30, 2007. Synta reported a net loss of $14.9 million or $0.45 per share for the quarter ending September 30, 2007, compared to a net loss of $14.7 million or $0.66 per share for the same period in 2006.
